CYTEK BIOSCIENCES, INC. Research and Development Expense
CYTEK BIOSCIENCES, INC. (CTKB) reported Research and Development Expense of $9.74 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- CYTEK BIOSCIENCES, INC. research and development expense for the quarter ending 2026-06-30 was $9.74M, a 10.37% increase year-over-year.
- CYTEK BIOSCIENCES, INC. research and development expense for the quarter ending 2026-03-31 was $9.60M, a 1.24% decline year-over-year.
- CYTEK BIOSCIENCES, INC. research and development expense for the quarter ending 2025-12-31 was $8.96M, a 7.83% decline year-over-year.
- CYTEK BIOSCIENCES, INC. research and development expense for the quarter ending 2025-09-30 was $8.96M, a 9.37% decline year-over-year.
- CYTEK BIOSCIENCES, INC. research and development expense for fiscal 2025 was $36.47M, a 7.45% decline from fiscal 2024.
- CYTEK BIOSCIENCES, INC. research and development expense for fiscal 2024 was $39.40M, a 10.76% decline from fiscal 2023.
- CYTEK BIOSCIENCES, INC. research and development expense for fiscal 2023 was $44.15M, a 26.66% increase from fiscal 2022.
- CYTEK BIOSCIENCES, INC. research and development expense for fiscal 2022 was $34.86M, a 42.62% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.74M 10-Q · filed 2026-08-05 | $19.34M 10-Q · filed 2026-08-05 | $28.31M derived: sum of 3 quarters · filed 2026-08-05 | $37.26M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $9.60M 10-Q · filed 2026-05-07 | $18.57M derived: sum of 2 quarters · filed 2026-05-07 | $27.52M derived: sum of 3 quarters · filed 2026-05-07 | $36.35M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $8.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $17.92M derived: sum of 2 quarters · filed 2026-02-26 | $26.74M derived: sum of 3 quarters · filed 2026-08-05 | $36.47M 10-K · filed 2026-02-26 |
| 2025-09-30 | $8.96M 10-Q · filed 2025-11-05 | $17.78M derived: sum of 2 quarters · filed 2026-08-05 | $27.51M 10-Q · filed 2025-11-05 | $37.23M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $8.83M 10-Q · filed 2026-08-05 | $18.55M 10-Q · filed 2026-08-05 | $28.27M derived: sum of 3 quarters · filed 2026-08-05 | $38.16M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $9.72M 10-Q · filed 2026-05-07 | $19.45M derived: sum of 2 quarters · filed 2026-05-07 | $29.33M derived: sum of 3 quarters · filed 2026-05-07 | $39.33M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $9.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $19.61M derived: sum of 2 quarters · filed 2026-02-26 | $29.61M derived: sum of 3 quarters · filed 2026-02-26 | $39.40M 10-K · filed 2026-02-26 |
| 2024-09-30 | $9.88M 10-Q · filed 2025-11-05 | $19.88M derived: sum of 2 quarters · filed 2025-11-05 | $29.68M 10-Q · filed 2025-11-05 | $40.55M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $10.00M 10-Q · filed 2025-08-06 | $19.80M 10-Q · filed 2025-08-06 | $30.67M derived: sum of 3 quarters · filed 2026-02-26 | $41.84M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $9.80M 10-Q · filed 2025-05-08 | $20.66M derived: sum of 2 quarters · filed 2026-02-26 | $31.84M derived: sum of 3 quarters · filed 2026-02-26 | $43.97M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $10.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $22.04M derived: sum of 2 quarters · filed 2026-02-26 | $34.18M derived: sum of 3 quarters · filed 2026-02-26 | $44.15M 10-K · filed 2026-02-26 |
| 2023-09-30 | $11.17M 10-Q · filed 2024-11-07 | $23.31M derived: sum of 2 quarters · filed 2024-11-07 | $33.28M 10-Q · filed 2024-11-07 | $43.03M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $12.14M 10-Q · filed 2024-08-06 | $22.11M 10-Q · filed 2024-08-06 | $31.86M derived: sum of 3 quarters · filed 2025-02-28 | $40.51M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $9.97M 10-Q · filed 2024-05-08 | $19.72M derived: sum of 2 quarters · filed 2025-02-28 | $28.37M derived: sum of 3 quarters · filed 2025-02-28 | $36.81M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $9.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $18.40M derived: sum of 2 quarters · filed 2025-02-28 | $26.83M derived: sum of 3 quarters · filed 2025-02-28 | $34.86M 10-K · filed 2025-02-28 |
| 2022-09-30 | $8.65M 10-Q · filed 2023-11-14 | $17.09M derived: sum of 2 quarters · filed 2023-11-14 | $25.11M 10-Q · filed 2023-11-14 | $32.19M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-06-30 | $8.44M 10-Q · filed 2023-08-08 | $16.46M 10-Q · filed 2023-08-08 | $23.54M derived: sum of 3 quarters · filed 2024-03-13 | $29.61M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-03-31 | $8.03M 10-Q · filed 2023-05-09 | $15.10M derived: sum of 2 quarters · filed 2024-03-13 | $21.18M derived: sum of 3 quarters · filed 2024-03-13 | $27.37M derived: sum of 4 quarters · filed 2024-03-13 |
| 2021-12-31 | $7.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $13.15M derived: sum of 2 quarters · filed 2024-03-13 | $19.35M derived: sum of 3 quarters · filed 2024-03-13 | $24.44M 10-K · filed 2024-03-13 |
| 2021-09-30 | $6.08M 10-Q · filed 2022-11-09 | $12.27M derived: sum of 2 quarters · filed 2022-11-09 | $17.37M 10-Q · filed 2022-11-09 | $21.75M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $6.19M 10-Q · filed 2022-08-10 | $11.29M 10-Q · filed 2022-08-10 | $15.67M derived: sum of 3 quarters · filed 2023-03-01 | $19.05M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $5.09M 10-Q · filed 2022-05-12 | $9.48M derived: sum of 2 quarters · filed 2023-03-01 | $12.86M derived: sum of 3 quarters · filed 2023-03-01 | $15.77M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $4.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $7.76M derived: sum of 2 quarters · filed 2023-03-01 | $10.68M derived: sum of 3 quarters · filed 2023-03-01 | $13.69M 10-K · filed 2023-03-01 |
| 2020-09-30 | $3.38M 10-Q · filed 2021-11-12 | $6.29M derived: sum of 2 quarters · filed 2021-11-12 | $9.31M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $2.92M 10-Q · filed 2021-09-03 | $5.93M 10-Q · filed 2021-09-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |